Sparrow Pharmaceuticals Secures $50 Million Series A Financing
Retrieved on:
星期二, 五月 18, 2021
b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.
Key Points:
- b'Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing.
- OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).
- This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues.
- To learn more about Sparrow Pharmaceuticals and its pipeline, visit the website at www.SparrowPharma.com .\nSparrow Pharmaceuticals was founded to spare patients the ravages of steroids.